Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 4.14
ZGNX's Cash-to-Debt is ranked higher than
53% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. ZGNX: 4.14 )
Ranked among companies with meaningful Cash-to-Debt only.
ZGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.73  Med: 1.83 Max: 6.99
Current: 4.14
0.73
6.99
Equity-to-Asset 0.52
ZGNX's Equity-to-Asset is ranked lower than
65% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. ZGNX: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
ZGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.27 Max: 0.6
Current: 0.52
0.09
0.6
Piotroski F-Score: 1
Altman Z-Score: -1.57
Beneish M-Score: 4.29
WACC vs ROIC
16.74%
-133.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -251.94
ZGNX's Operating Margin % is ranked lower than
91% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. ZGNX: -251.94 )
Ranked among companies with meaningful Operating Margin % only.
ZGNX' s Operating Margin % Range Over the Past 10 Years
Min: -299.29  Med: -175.58 Max: 142.89
Current: -251.94
-299.29
142.89
Net Margin % -241.62
ZGNX's Net Margin % is ranked lower than
91% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. ZGNX: -241.62 )
Ranked among companies with meaningful Net Margin % only.
ZGNX' s Net Margin % Range Over the Past 10 Years
Min: -313.81  Med: -223.29 Max: 96.18
Current: -241.62
-313.81
96.18
ROE % -44.90
ZGNX's ROE % is ranked lower than
86% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. ZGNX: -44.90 )
Ranked among companies with meaningful ROE % only.
ZGNX' s ROE % Range Over the Past 10 Years
Min: -491.54  Med: -222.19 Max: 23.3
Current: -44.9
-491.54
23.3
ROA % -25.79
ZGNX's ROA % is ranked lower than
83% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. ZGNX: -25.79 )
Ranked among companies with meaningful ROA % only.
ZGNX' s ROA % Range Over the Past 10 Years
Min: -164.96  Med: -83.71 Max: 10.28
Current: -25.79
-164.96
10.28
ROC (Joel Greenblatt) % -374.81
ZGNX's ROC (Joel Greenblatt) % is ranked lower than
87% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.39 vs. ZGNX: -374.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -508.05  Med: -389.19 Max: 547.3
Current: -374.81
-508.05
547.3
3-Year Revenue Growth Rate -21.80
ZGNX's 3-Year Revenue Growth Rate is ranked lower than
91% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. ZGNX: -21.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50.45 Max: -21.8
Current: -21.8
3-Year EBITDA Growth Rate -6.00
ZGNX's 3-Year EBITDA Growth Rate is ranked lower than
76% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. ZGNX: -6.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ZGNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -70.1 Max: -6
Current: -6
3-Year EPS without NRI Growth Rate -19.70
ZGNX's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. ZGNX: -19.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ZGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -66.4 Max: -19.7
Current: -19.7
GuruFocus has detected 4 Warning Signs with Zogenix Inc $ZGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ZGNX Guru Trades in Q1 2016

Paul Tudor Jones 16,400 sh (-1.28%)
Jim Simons 74,087 sh (-45.88%)
» More
Q2 2016

ZGNX Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Jim Simons 37,187 sh (-49.81%)
» More
Q3 2016

ZGNX Guru Trades in Q3 2016

Jim Simons 93,287 sh (+150.86%)
» More
Q4 2016

ZGNX Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:BAYRY » details
Traded in other countries:Z081.Germany,
Zogenix Inc is a pharmaceutical company engaged in commercializing & developing therapies that address clinical needs for people living with pain-related and CNS disorders that needs treatment alternatives to help return to normal daily functioning.

Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA. Its trademarks include DosePro, Relday, Zogenix and Zohydro ER. The Company is subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or FFDCA, and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
PB Ratio 2.23
ZGNX's PB Ratio is ranked higher than
64% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. ZGNX: 2.23 )
Ranked among companies with meaningful PB Ratio only.
ZGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 3.99 Max: 543.53
Current: 2.23
1.15
543.53
PS Ratio 9.35
ZGNX's PS Ratio is ranked lower than
81% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. ZGNX: 9.35 )
Ranked among companies with meaningful PS Ratio only.
ZGNX' s PS Ratio Range Over the Past 10 Years
Min: 0.3  Med: 5.85 Max: 14.79
Current: 9.35
0.3
14.79
Current Ratio 5.90
ZGNX's Current Ratio is ranked higher than
81% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. ZGNX: 5.90 )
Ranked among companies with meaningful Current Ratio only.
ZGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.89 Max: 6.15
Current: 5.9
1.25
6.15
Quick Ratio 5.56
ZGNX's Quick Ratio is ranked higher than
83% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.75 vs. ZGNX: 5.56 )
Ranked among companies with meaningful Quick Ratio only.
ZGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.25  Med: 1.5 Max: 5.75
Current: 5.56
1.25
5.75
Days Inventory 161.83
ZGNX's Days Inventory is ranked lower than
73% of the 642 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. ZGNX: 161.83 )
Ranked among companies with meaningful Days Inventory only.
ZGNX' s Days Inventory Range Over the Past 10 Years
Min: 154.96  Med: 193.2 Max: 419.33
Current: 161.83
154.96
419.33
Days Sales Outstanding 159.12
ZGNX's Days Sales Outstanding is ranked lower than
87% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. ZGNX: 159.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.75  Med: 69.66 Max: 159.12
Current: 159.12
18.75
159.12
Days Payable 73.90
ZGNX's Days Payable is ranked higher than
51% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. ZGNX: 73.90 )
Ranked among companies with meaningful Days Payable only.
ZGNX' s Days Payable Range Over the Past 10 Years
Min: 73.9  Med: 85.06 Max: 148.78
Current: 73.9
73.9
148.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.60
ZGNX's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. ZGNX: -12.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -348.1  Med: -29.1 Max: 0
Current: -12.6
-348.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 29.46
ZGNX's Price-to-Net-Current-Asset-Value is ranked lower than
87% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. ZGNX: 29.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ZGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 5.94  Med: 22.24 Max: 32.84
Current: 29.46
5.94
32.84
Price-to-Tangible-Book 22.24
ZGNX's Price-to-Tangible-Book is ranked lower than
93% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. ZGNX: 22.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ZGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.93  Med: 12.42 Max: 25.94
Current: 22.24
4.93
25.94
Price-to-Median-PS-Value 1.60
ZGNX's Price-to-Median-PS-Value is ranked lower than
70% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. ZGNX: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.15 Max: 1.92
Current: 1.6
0.08
1.92
Earnings Yield (Greenblatt) % -33.27
ZGNX's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. ZGNX: -33.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -36.44  Med: 41 Max: 20885.8
Current: -33.27
-36.44
20885.8

More Statistics

Revenue (TTM) (Mil) $28.85
EPS (TTM) $ -2.81
Beta1.96
Short Percentage of Float24.10%
52-Week Range $7.33 - 13.70
Shares Outstanding (Mil)24.81

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 34 61
EPS ($) -4.79 -1.37
EPS without NRI ($) -4.79 -1.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix, Inc. :ZGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Zogenix, Inc. :ZGNX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
ZOGENIX, INC. Financials Mar 15 2017
Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference Mar 15 2017
ZOGENIX, INC. Files SEC form 10-K, Annual Report Mar 10 2017
Zogenix reports 4Q loss Mar 09 2017
Zogenix reports 4Q loss Mar 09 2017
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 09 2017
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results Mar 09 2017
Q4 2016 Zogenix Inc Earnings Release - After Market Close Mar 09 2017
Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and... Mar 02 2017
Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome Mar 01 2017
ZOGENIX, INC. Files SEC form 8-K, Other Events Mar 01 2017
Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference Feb 15 2017
Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome Feb 13 2017
Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference Feb 08 2017
ZOGENIX, INC. Files SEC form 8-K, Other Events Jan 30 2017
Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome Jan 30 2017
Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for... Jan 26 2017
ZOGENIX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)